Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
125I Seed Brachytherapy + Immunotherapy in Malignant Tumors
NCT07277777Phase 2Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in malignant neoplasm (2 arms). Primary endpoints: Objective Response Rate and Progression-Free Survival up to 24 months. Planned start Jan 2026; status: not yet recruiting.
02
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT07277777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277777.